Rapid phagosome formation drives parasite control in subclinical Leishmania braziliensis infection - Takeaways - MDSpire

Rapid phagosome formation drives parasite control in subclinical Leishmania braziliensis infection

  • By

  • Caic Figueiredo

  • Alan Rocha dos Santos

  • Camila Pimentel

  • Maurício T. Nascimento

  • Fabio Peixoto

  • Vítor Oliveira

  • Olivia Bacellar

  • Lucas P. Carvalho

  • Edgar M. Carvalho

  • Thiago M. Cardoso

  • June 5, 2026

  • 0 min

Share

  • 1

    Subclinical (SC) individuals with Leishmania braziliensis infection show effective control of parasites without developing cutaneous leishmaniasis (CL).

  • 2

    SC macrophages (MØ) exhibit accelerated phagosome formation compared to CL MØ, enhancing their ability to kill L. braziliensis.

  • 3

    Higher expression of lysosome-associated membrane protein-1 (LAMP-1) in SC MØ correlates with improved parasite control during early infection stages.

  • 4

    SC MØ maintain effective parasite killing for extended periods, demonstrating a robust immune response despite lower pro-inflammatory cytokine production.

  • 5

    The study highlights the importance of rapid phagosome maturation in SC MØ for effective control of intracellular Leishmania parasites.

Original Source(s)

Rapid phagosome formation drives parasite control in subclinical Leishmania braziliensis infection

  • by Caic Figueiredo, Alan Rocha dos Santos, Camila Pimentel, Maurício T. Nascimento, Fabio Peixoto, Vítor Oliveira, Olivia Bacellar, Lucas P. Carvalho, Edgar M. Carvalho, Thiago M. Cardoso

  • June 5, 2026

Related Content

Rare or Unverified Outcomes Shape Vaccine Safety and Gender Care Debates — The Monitor

Weekly HIV Regimen Meets Phase 3 Goal

The investigational combination pairs islatravir and lenacapavir in a once-weekly single-tablet regimen.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.